Moderna and Merck report late-stage success for personalized mRNA cancer vaccine

Moderna and Merck announced that their personalized cancer vaccine achieved its primary goals in a late-stage clinical trial, sparking enthusiasm across the biotech community.

The experimental therapy, called intismeran autogene, is designed to be tailored to each patient by using a computer algorithm to select the exact mRNA sequence that will trigger an immune response against the tumor.

If regulators grant approval, the product would represent a landmark in both immunology and cancer treatment, as it would be the first approved drug whose genetic code is generated by an algorithm rather than a fixed formula.